Related Experiment Video
Updated: Oct 17, 2026

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
Published on: July 18, 2025
Hepatocyte senescence in metabolic dysfunction-associated steatotic liver disease (MASLD)
Xinyue Pang1, Nan Geng2, Chenqi Lu2
1Department of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, Jiangsu, China.
Abstract:
Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as a major global health challenge, with particularly high morbidity and disease burden. Cellular senescence has been identified as one of the core mechanisms driving the onset and progression of MASLD. Hepatocytes, the primary functional cells of the liver, can undergo a senescent state under metabolic stress. These senescent hepatocytes secrete a series of pro-inflammatory and profibrotic factors, directly exacerbating hepatic inflammation and activating hepatic stellate cells, thereby leading to pathological fibrosis. The purpose of this review is to explore the key molecular pathways of hepatocyte senescence and their impact on MASLD progression. Finally, we discuss relevant intervention strategies that can be used for the prevention and treatment of MASLD.
Related Concept Videos
Cirrhosis II: Pathophysiology
Cirrhosis I: Introduction
Liver Regeneration
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are large...
Chronic Pancreatitis II: Pathophysiology
